Bright Minds Biosciences Inc.
DRUG · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | -0.05 | -0.01 |
| FCF Yield | -27.13% | -86.97% | -64.68% | -9.01% |
| EV / EBITDA | 0.00 | -0.19 | -0.65 | 0.00 |
| Quality | ||||
| ROIC | -46.27% | -107.91% | -137.91% | -44.44% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.95 | 0.91 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 73.66% | 48.30% | -85.63% | -2,437.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.92 | 0.78 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |